drugset / Trial / NCT06326476
Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.
Timeline
- Start
- 2025-05-09
- Primary completion
- 2027-12-31
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siplizumab | Monoclonal antibody | 10 mg | Subcutaneous |
| Subject | Siplizumab | Monoclonal antibody | 20 mg | Subcutaneous |
| Subject | Siplizumab | Monoclonal antibody | 40 mg | Subcutaneous |